Macrolide Use and Neutrophil Function/Cytokine Levels in Hospitalized Patients with Community-Acquired Pneumonia: A Pilot Study

Lung

Volumn 194, Issue 1, 2016, Pages 155-162

  Arnold, Forest W ^a   Bordon, Jose ^b   Fernandez Botran, Rafael ^a   Rane, Madhavi J ^a   Uriarte, Silvia M ^a   Kelley, Robert ^a   Wiemken, Timothy L ^a   Peyrani, Paula ^a   Ramirez, Julio A ^a  

^a University of Louisville School of Medicine   (United States)

^b Providence Hospital Washington DC   (United States)

Author keywords

Anti inflammatory cytokines; Community acquired pneumonia; Mortality; Neutrophil function; Pro inflammatory cytokines

Indexed keywords

GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; PNEUMOCOCCUS VACCINE; ANTIINFECTIVE AGENT; AZITHROMYCIN; CYTOKINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGRANULATION; DRUG USE; FEMALE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MALE; NEUTROPHIL; OUTCOME ASSESSMENT; PHAGOCYTOSIS; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECRETORY VESICLE; AGED; BLOOD; COMMUNITY-ACQUIRED INFECTIONS; DRUG EFFECTS; HOSPITAL MORTALITY; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; PNEUMONIA; RESPIRATORY BURST;

AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CELL DEGRANULATION; COMMUNITY-ACQUIRED INFECTIONS; CYTOKINES; FEMALE; HOSPITAL MORTALITY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; INTERLEUKIN-8; LENGTH OF STAY; MALE; MIDDLE AGED; NEUTROPHILS; PHAGOCYTOSIS; PILOT PROJECTS; PNEUMONIA; PROSPECTIVE STUDIES; RESPIRATORY BURST;

EID: 84957838570     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-015-9822-7     Document Type: Article

References (19)

1. Hoyert DL, Xu J (2012) Deaths: preliminary data for 2011. Natl Vital Stat Rep 61:38
2. Mandell LA, Wunderink RG, Anzueto A et al (2007) Infectious diseases Society Of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(suppl2):S27–S72
3. Demartini G, Esposti D, Marthyn P et al (2004) Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFN-γ and IL-10 plasma levels in patients with community-acquired pneumonia. J Chemther 16:82–85
4. Lagrou K, Peetermans WE, Jorissen M et al (2000) Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro. J Antimicrob Chem 46:717–723
5. Koch CC, Esteban DJ, Chin AC et al (2000) Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of streptococcus pneumoniae. J Antimicrob Chem 46:19–26
6. Uriarte SM, Rane MJ, Luerman GC et al (2011) Granule exocytosis contributes to priming and activation of the human neutrophil respiratory burst. J Immunol 187:391–400
7. Haslett C, Guthrie LA, Kopaniak MM et al (1985) Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide. Am J Pathol 119:101–110
8. Ward RA, Nakamura M, McLeish KR (2000) Priming of the neutrophil respiratory burst involves p38 mitogen-activated protein kinase-dependent exocytosis of flavocytochrome b558-containing granules. J Biol Chem 275:36713–36719
9. Fernandez-Botran R, Uriarte SM, Arnold FW et al (2014) Contrasting inflammatory responses in severe and non-severe community-acquired pneumonia. Inflammation 37:1158–1166
10. Khair OA, Devalia JL, Abdelaziz MM et al (1995) Effect of erythromycin on haemophilus influenzae endotoxin-induced release of il-6, il-8 and sicam-1 by cultured human bronchial epithelial cells. Eur Resp J 8:1451–1457
11. Rios AM, Mejias A, Chavez-Bueno S et al (2004) Impact of cethromycin (abt-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of mycoplasma pneumoniae lower respiratory infection. Antimicrob Agents Chemother 48:2897–2904
12. Rios AM, Fonseca-Aten M, Mejias A et al (2005) Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 49:3970–3973
13. Rodrigo C, Mckeever TM, Woodhead M et al (2013) Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax 68:493–495
14. Arnold FW, Summersgill JT, Lajoie AS et al (2007) A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Resp Crit Care Med 175:1086–1093
15. Kovaleva A, Remmelts HHF, Rijkers GT et al (2012) Immunomodulatory effects of macrolides during community-acquired pneumonia. J Antimicrob Chemother 67:530–540
16. Restrepo MI, Mortensen EM, Waterer GW et al (2009) Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Resp J 33:153–159
17. Martin-Loeches I, Lisboa T, Rodriguez A et al (2010) Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 36:612–620
18. Asadi L, Sligl WI, Eurich DT et al (2012) Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 55:371–380
19. Yanagihara K, Izumikawa K, Higa F et al (2009) Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant streptococcus pneumoniae infection. Internal Med 48:527–535